Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer.
Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Carlos Triviño J, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Francisco Rodríguez Moreno J, Fernández Aramburo A, López C, Maroto P, Sastre J, José Juan Fita M, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, María Autran A, Benítez J. Paumard-Hernández B, et al. Among authors: quiroga v. Int J Cancer. 2018 Oct 15;143(8):1954-1962. doi: 10.1002/ijc.31604. Epub 2018 Aug 9. Int J Cancer. 2018. PMID: 29761480 Free article.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J, Sánchez-Muñoz A, Ochenduszko S, Gumà J, Fernández-Aramburo A, García Del Muro X, Quiroga V, Sastre J, Alonso-Gordoa T, Sagastibelza N, Maroto P, Gómez de Liaño A, Vázquez S, Diz P, Durán I, Domenech M, Pinto A, Hernández A, González-Billalabeitia E, Terrasa J. Aparicio J, et al. Among authors: quiroga v. J Urol. 2019 Oct;202(4):742-747. doi: 10.1097/JU.0000000000000366. Epub 2019 Sep 6. J Urol. 2019. PMID: 31163007
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andrés R, Santisteban M, Ramos M, Holgado E, Cortés J, López-Miranda E, Cortés A, Henao F, Palazón-Carrión N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, Jiménez-Cortegana C, Sánchez-Margalet V, Rojo F. de la Cruz-Merino L, et al. Among authors: quiroga v. BMC Cancer. 2022 Dec 3;22(1):1258. doi: 10.1186/s12885-022-10363-3. BMC Cancer. 2022. PMID: 36463104 Free PMC article. Clinical Trial.
Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).
Morán T, Quiroga V, Gil Mde L, Vilà L, Pardo N, Carcereny E, Capdevila L, Muñoz-Mármol AM, Rosell R. Morán T, et al. Among authors: quiroga v. Transl Lung Cancer Res. 2013 Apr;2(2):128-41. doi: 10.3978/j.issn.2218-6751.2013.03.04. Transl Lung Cancer Res. 2013. PMID: 25806224 Free PMC article. Review. No abstract available.
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.
Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB. Panciroli C, et al. Among authors: quiroga v. Clin Transl Oncol. 2020 Mar;22(3):411-419. doi: 10.1007/s12094-019-02143-6. Epub 2019 May 29. Clin Transl Oncol. 2020. PMID: 31144211
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AM, Quiroga V, Santaballa Bertran A, Mina L, Bellosillo B, Rojo F, Menéndez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortés J, Llombart-Cussac A. Albanell J, et al. Among authors: quiroga v. Clin Cancer Res. 2023 Jan 4;29(1):67-80. doi: 10.1158/1078-0432.CCR-22-1281. Clin Cancer Res. 2023. PMID: 36165912 Free PMC article. Clinical Trial.
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Teruel I, Castellà E, Recalde S, Viñas G, Petit A, Trigueros M, Martínez-Balibrea E, Felip E, Bergamino M, Bernat-Peguera A, Cirauqui B, Quiroga V, Ferrando-Díez A, Pous A, López A, Boronat L, Soler G, Recuero J, Romeo M, Guillén P, Mesía R, Ballana E, Martínez-Cardús A, Margelí M. Teruel I, et al. Among authors: quiroga v. Int J Mol Sci. 2024 Nov 14;25(22):12241. doi: 10.3390/ijms252212241. Int J Mol Sci. 2024. PMID: 39596307 Free PMC article.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM, Montaño A, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri MJ, Muñoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. Ciruelos EM, et al. Among authors: quiroga v. Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23. Eur J Cancer Care (Engl). 2020. PMID: 32578279 Clinical Trial.
53 results